Inactive Instrument

AS Olainfarm

OLF1R

LV0000100501

AS Olainfarm Provides Earnings Guidance for the Year 2020

May 29, 2020 at 10:02 am

AS Olainfarm provided earnings guidance for the year 2020. For 2020, the Group estimates its revenue to be EUR 135.5 million. The Group's net profit target for 2020 remains unchanged at the amount of EUR 14.2 million.

Latest news about AS Olainfarm

AS "AB CITY" completed the acquisition of an additional 49.19% stake in AS Olainfarm from a group of shareholders for €64.2 million.	21-12-06	CI
Olainfarm Board OKs AB City's Mandatory Share Buyback Offer	21-11-12	MT
AS Olainfarm : AB City Plans to Initiate Mandatory Repurchase Offer for Olainfarm Shares	21-09-30	MT
AS "AB CITY" made an offer to acquire an additional 50.8% stake in AS Olainfarm from a group of shareholders for €66.3 million.	21-09-29	CI
Transcript : AS Olainfarm, Q2 2021 Earnings Call, Aug 31, 2021	21-08-31
As Olainfarm Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-31	CI
AS "AB CITY" completed the acquisition of 48.08% stake in AS Olainfarm for ?62.7 million.	21-08-24	CI
Janis Buks Elected as the Chairperson of the Management Board of JSC Olainfarm	21-07-30	CI
AS "AB CITY" made a mandatory bid to acquire 69.2% stake in AS Olainfarm for ?90.2 million.	21-07-04	CI
AS Olainfarm Approves Dividend for the Year 2020, Payable on July 12, 2021	21-06-18	CI
JSC Olainfarm Announces Board Appointments	21-06-18	CI
JSC Olainfarm Announces Management Changes	21-06-17	CI
JSC “Olainfarm” Elects Audit Committee	21-06-16	CI
JSC Olainfarm & Adalvo to Launch New Urology Product in 17 Countries in 2022-2023	21-06-16	CI
Black Duck Invest a.s. agreed to acquire 42.6% stake in AS Olainfarm from SIA Olmafarm for €30 million.	21-06-10	CI
Black Duck Invest a.s. completed the acquisition of 42.3% stake in AS Olainfarm from SIA Olmafarm for €30 million.	21-06-10	CI
Jeroen Weites Leaves Position as Chairperson of JSC Olainfarm	21-06-08	CI
AS Olainfarm Proposes Dividend, Payable on July 12, 2021	21-06-04	CI
Transcript : AS Olainfarm, Q1 2021 Earnings Call, Jun 02, 2021	21-06-02
As Olainfarm Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-28	CI
JSC Olainfarm Receives an Application from the Current Member of the Management Board Zane Kotane to Resign from May 19	21-05-19	CI
Black Duck Invest Intends to Acquire Stake in Olainfarm	21-05-09	CI
Milana Belevica Leaves Her Position as the Member of the Management Board of JSC Olainfarm	21-04-29	CI
As Olainfarm Reports Earnings Results for the Full Year Ended December 31, 2020	21-04-14	CI
Olainfarm Considers Participating in Building A Vaccine Manufacturing Plant	21-03-11	CI

Chart AS Olainfarm

Duration

Period

More charts

Company Profile

Olainfarm AS is a Latvia-based company engaged in the pharmaceutical sector. The Company is active in the production of basic pharmaceutical products and pharmaceutical preparations. The Company's activities include numerous finished forms of medicaments with effects, which include cardiological, neurologic, diuretic, spasmologic and antiallergic drug preparations, medicaments treating the digestive system, antibiotics and food supplements, as well as various active chemical ingredients and raw chemical materials. Its products include Amlodipine, Clonazepam, Euphillin, Furosemide, Furagin, Midolat, Protionol and Gripoflex, among others. The Company operates through its subsidiaries which includes Reinolds SIA, Ozols JDR SIA, Olainfarm energija SIA, Ilmas Aptiekas SIA and Veritas-Farm, among others. In addition, the Company has 33 pharmacies, located in Riga, Vidzeme, Kurzeme and Latgale. In May 2013, it acquired a 47.5% shares in pharmaceutical manufacturer SIA Silvanols.

Sector

Pharmaceuticals

More about the company

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
SUN PHARMACEUTICAL INDUSTRIES LTD.	+21.60%	44.15B
OTSUKA HOLDINGS CO., LTD.	+23.03%	23.02B
SANDOZ GROUP AG	+20.29%	15.33B
CIPLA LIMITED	+12.28%	13.74B
ZYDUS LIFESCIENCES LIMITED	+53.33%	12.16B
ONO PHARMACEUTICAL CO., LTD.	-10.02%	6.84B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+13.88%	5.66B

Generic Pharmaceuticals